Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
| Autor: | Audrey Bidet, Hubert Serve, Pierre-Yves Dumas, Carsten Müller-Tidow, Josefina Serrano, Teresa Bernal, Sarah Bertoli, Juan Bergua, Eduardo Rodriguez Arbolí, Uwe Platzbecker, Pilar Martínez-Sánchez, Martin Bornhäuser, Eric Delabesse, Adolfo de la Fuente Burguera, Christian Recher, Arnaud Pigneux, Michael Kramer, Claudia D. Baldus, David Martínez-Cuadrón, Pau Montesinos, Emilie Bérard, Cristina Gil, Christoph Röllig, Suzanne Tavitian |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment EARLY DEATH NEWLY-DIAGNOSED AML Intensive chemotherapy ACUTE MYELOID-LEUKEMIA REGIMENS Lower risk Internal medicine Antineoplastic Combined Chemotherapy Protocols Long term survival MANAGEMENT Humans Medicine In patient VENETOCLAX Registries ELDERLY-PATIENTS AZACITIDINE Aged Aged 80 and over Chemotherapy EPIGENETIC THERAPY business.industry Significant difference Myeloid leukemia Hematology Patient data CARE Leukemia Myeloid Acute Treatment Outcome Oncology Azacitidine business |
| Zdroj: | Leukemia r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname LEUKEMIA r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante |
| ISSN: | 0887-6924 |
| Popis: | The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric European database collecting data of 3 700 newly diagnosed acute myeloid leukemia patients ≥70 years. The primary objective was to compare overall survival in patients selected for intensive chemotherapy (n = 1199) or hypomethylating agents (n = 1073). With a median follow-up of 49.5 months, the median overall survival was 10.9 (95% CI: 9.7–11.6) and 9.2 months (95% CI: 8.3–10.2) with chemotherapy and hypomethylating agents, respectively. Complete remission or complete remission with incomplete hematologic recovery was 56.1% and 19.7% with chemotherapy and hypomethylating agents, respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink